Table 6.
Univariate Cox regression analysis of the survival-associated hub genes in MIBC patients receiving neoadjuvant cisplatin-based chemotherapy (HR: hazard ratio, CI: confidence interval, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, **** p-value < 0.0001).
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| RFS-Related Gene | HR (95% CI) | p-Value | HR (95% CI) | p-Value |
| ANXA5 | 1.1 (0.70–1.70) | 0.7 | 0.42 (0.24–0.74) | 0.00268 ** |
| CD44 | 1.3 (0.99–1.70) | 0.055 | 1.65 (1.20–2.28) | 0.00220 ** |
| NCAM1 | 1.1 (0.81–1.60) | 0.48 | 1.60 (1.09–2.35) | 0.01718 * |
| IGF1 | 0.48 (0.24–0.98) | 0.043 * | -- | -- |
| SPP1 | 1.5 (1.30–1.80) | 3.3 × 10−6 **** | 1.72 (1.42–2.09) | 2.93 × 10−8 **** |
| CDCA8 | 0.5 (0.26–0.96) | 0.037 * | 0.18 (0.08–0.42) | 5.72 × 10−5 **** |
| KIF14 | 1.8 (0.87–3.70) | 0.11 | 4.68 (2.17–10.11) | 8.59 × 10−5 **** |
| CSS-Related Gene | HR (95% CI) | p -Value | ||
| ANXA5 | 1.1 (0.68–1.70) | 0.74 | 0.44 (0.24–0.82) | 0.009708 ** |
| CD44 | 1.3 (0.95–1.60) | 0.11 | 1.60 (1.12–2.29) | 0.009785 ** |
| NCAM1 | 1.1 (0.82–1.60) | 0.47 | 1.43 (0.99–2.05) | 0.049989 * |
| SPP1 | 1.4 (1.20–1.70) | 5.8 × 10−5 **** | 1.64 (1.35–2.01) | 1.15 × 10−6 **** |
| CDCA8 | 0.48 (0.24–0.94) | 0.034 * | 0.17 (0.07–0.41) | 6.49 × 10−5 **** |
| KIF14 | 1.7 (0.84–3.60) | 0.14 | 4.82 (2.12–10.96) | 0.000171 *** |
| OS-Related Gene | HR (95% CI) | p -Value | ||
| ACTG2 | 1.3 (1.00–1.60) | 0.038 * | -- | -- |
| ANXA5 | 0.97 (0.63–1.50) | 0.9 | 0.41 (0.23–0.72) | 0.002139 ** |
| CD44 | 1.2 (0.96–1.60) | 0.095 | 1.63 (1.17–2.28) | 0.003812 ** |
| NCAM1 | 1.1 (0.82–1.50) | 0.48 | 1.42 (1.00–2.01) | 0.047272 * |
| SPP1 | 1.4 (1.20–1.60) | 0.00012 *** | 1.60 (1.32–1.92) | 1.1 × 10−6 **** |
| CDCA8 | 0.48 (0.25–0.91) | 0.024 * | 0.19 (0.09–0.42) | 5.0 × 10−5 **** |
| KIF14 | 1.6 (0.78–3.20) | 0.21 | 4.45 (2.01–9.85) | 0.000225 *** |